BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3468422)

  • 1. Economics of screening for cancer of the cervix.
    Hicks S; Edwards D
    N Z Med J; 1986 Nov; 99(814):916. PubMed ID: 3468422
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic aspects of screening for cervical cancer in New Zealand.
    Bethwaite J; Rayner T; Bethwaite P
    N Z Med J; 1986 Oct; 99(811):747-51. PubMed ID: 3464889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Costs and problems in cervix cancer screening are considerably underestimated].
    Bistoletti P
    Lakartidningen; 2000 Aug; 97(32-33):3506-8. PubMed ID: 11037597
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics of screening for cancer of the cervix.
    Hicks S; Edwards D
    N Z Med J; 1987 Feb; 100(817):81. PubMed ID: 3469553
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cytological mass screenings for the cancer of the cervix uteri. Resources, organization and costs].
    Kolstad P
    Tidsskr Nor Laegeforen; 1988 Sep; 108(25):2057-60. PubMed ID: 3201418
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of cervical-cancer screening in developing countries.
    Suba EJ; Frable WJ; Raab SS
    N Engl J Med; 2006 Apr; 354(14):1535-6; author reply 1535-6. PubMed ID: 16598056
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cervix cancer screening can be cost-effective. Combination of vaginal smears and the HPV test should be even more beneficial].
    Bistoletti P; Ellström A; Dillner J; Sennfält K; Sparén P; Strander B
    Lakartidningen; 2005 Jun 13-26; 102(24-25):1874-6, 1878-9. PubMed ID: 16044766
    [No Abstract]   [Full Text] [Related]  

  • 8. Papanicolaou cervical smears for screening in asymptomatic women.
    Barnes BA
    Prim Care; 1981 Mar; 8(1):131-40. PubMed ID: 6911755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of screening for cervical cancer.
    Coldman AJ; Anderson GH
    N Z Med J; 1987 Jul; 100(827):425. PubMed ID: 3452069
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cervical cancer screening and associated treatment costs in France].
    Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer screening in primary care: issues and recommendations.
    Mandelblatt J
    Prim Care; 1989 Mar; 16(1):133-55. PubMed ID: 2649899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the sensitivity of cervical cytology: what are the issues?
    Myers ER
    Am J Manag Care; 2000 Jul; 6(7):838-40. PubMed ID: 11067380
    [No Abstract]   [Full Text] [Related]  

  • 13. Cervical screening program for Sri Lanka--can we afford it?
    Sirisena J
    Ceylon Med J; 1999 Mar; 44(1):41-5. PubMed ID: 10643099
    [No Abstract]   [Full Text] [Related]  

  • 14. [A reply on cervix cancer screening: cervical cytological test doesn't fulfil the requirements of a good screening test].
    Bistoletti P
    Lakartidningen; 2000 Sep; 97(37):4042. PubMed ID: 11036367
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cervix cancer screening: results of a french team].
    Salvat J; Slamani L; Schmidt MH
    Rev Med Suisse Romande; 1997 Aug; 117(8):593-6. PubMed ID: 9340713
    [No Abstract]   [Full Text] [Related]  

  • 16. Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?
    Reust CE
    J Fam Pract; 2001 Feb; 50(2):175. PubMed ID: 11219567
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicare expands preventive screening benefits.
    Moore KJ
    Fam Pract Manag; 2001 Jun; 8(6):16. PubMed ID: 11547392
    [No Abstract]   [Full Text] [Related]  

  • 18. Prospects for newer technologies in cervical cancer screening programmes.
    Hailey DM; Lea R
    J Qual Clin Pract; 1995 Sep; 15(3):139-45. PubMed ID: 8528539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of population screening and rescreening for cervical cancer in the Netherlands.
    Boon ME; de Graaff Guilloud JC
    Acta Cytol; 1981; 25(5):539-42. PubMed ID: 6792845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.